Preclinical compounds for the treatment of overactive bladder

Overactive bladder is a prevalent and bothersome condition. Existing pharmacotherapy with antimuscarinics improves symptoms and quality of life but there are certain limitations in efficacy and tolerability. To review novel, recently patented compounds for the treatment of overactive bladder. The Eu...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on therapeutic patents Vol. 19; no. 2; p. 107
Main Authors Giannitsas, Konstantinos, Konstantinopoulos, Angelis, Patsialas, Christos, Athanasopoulos, Anastasios, Perimenis, Petros
Format Journal Article
LanguageEnglish
Published England 01.02.2009
Subjects
Afferent Pathways - drug effects
Afferent Pathways - metabolism
Animals
Drug Evaluation, Preclinical
Humans
Muscarinic Antagonists - adverse effects
Muscarinic Antagonists - therapeutic use
Patents as Topic
Quality of Life
Urinary Bladder, Overactive - drug therapy
Urinary Bladder, Overactive - physiopathology
Online AccessGet more information

Cover

More Information
Summary:Overactive bladder is a prevalent and bothersome condition. Existing pharmacotherapy with antimuscarinics improves symptoms and quality of life but there are certain limitations in efficacy and tolerability. To review novel, recently patented compounds for the treatment of overactive bladder. The European Patent Office database was searched for compounds that emerged in the last 3 years. Overactive bladder pathophysiology and treatment is an active field of research. Molecules that modulate/inhibit afferent nerve pathways are the focus of interest and the most promising field of overactive bladder drug development.
ISSN:1744-7674
DOI:10.1517/13543770802672606